IndiaCOVID-19Ministry of Health and Family WelfareHealth

COVID – 19 Vaccination Update – Day 419

India’s cumulative vaccination coverage crosses 179.69 Crore. More than 14 lakh Vaccine doses administered today till 7 pm

India’s COVID-19 vaccination coverage has crossed 179.69 Crore (1,79,69,92,789) today. More than 14 lakh (14,74,342Vaccine Doses have been administered till 7 pm today. More than 2.10 Crore (2,10,45,028) Precaution Doses for the identified categories of beneficiaries (HCWs, FLWs and Over 60 years) for COVID vaccination have been administered so far. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

The cumulative coverage of vaccine doses, segregated based on population priority groups, is as follows:

Cumulative Vaccine Dose Coverage
HCWs 1st Dose 10402436
2nd Dose 9981609
Precaution Dose 4288858
FLWs 1st Dose 18411143
2nd Dose 17471956
Precaution Dose 6493338
Age Group 15-18 years 1st Dose 55713531
  2nd Dose 32858434
Age Group 18-44 years 1st Dose 553061431
2nd Dose 453259446
Age Group 45-59 years 1st Dose 202481497
2nd Dose 182243161
Over 60 years 1st Dose 126561752
2nd Dose 113501365
Precaution Dose 10262832
Cumulative 1st dose administered 966631790
Cumulative 2nd dose administered 809315971
Precaution Dose 21045028
Total 1796992789

 

Today’s achievement in the vaccination exercise, segregated by population priority groups, is as follows:

Date: 10th March, 2022 (419th Day)
HCWs 1st Dose 50
2nd Dose 1303
Precaution Dose 8669
FLWs 1st Dose 88
2nd Dose 2847
Precaution Dose 15155
Age Group 15-18 years 1st Dose 54180
  2nd Dose 335828
Age Group 18-44 years 1st Dose 77801
2nd Dose 653844
Age Group 45-59 years 1st Dose 11852
2nd Dose 154233
Over 60 years 1st Dose 8008
2nd Dose 98661
Precaution Dose 51823
Cumulative 1st dose administered 151979
Cumulative 2nd dose administered 1246716
Precaution Dose 75647
Total 1474342

 

The vaccination exercise as a tool to protect the most vulnerable population groups in the country from COVID-19 continues to be regularly reviewed and monitored at the highest level.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Comment moderation is enabled. Your comment may take some time to appear.

Back to top button

Adblock detected

Please consider supporting us by disabling your ad blocker